# Jason R. Westin

Source: https://onco.cc/people/jason-westin/  
OnCo record `jason-westin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma.

## Summary

Jason Westin was first author of the ZUMA-7 overall survival report, which showed axicabtagene ciloleucel improves survival compared with standard chemoimmunotherapy and transplant in primary refractory or early relapsed large B-cell lymphoma, the first randomised survival benefit for a CAR-T therapy and the trial that moved CAR-T into second line. He leads the Smart Start precision-medicine trials in DLBCL and lymphoma clinical research at MD Anderson.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; car-t; second-line
- Role: Director of Lymphoma Clinical Research, MD Anderson Cancer Center
- Specialisms: Large B-cell lymphoma; CAR T-cell therapy; Second-line therapy; Precision medicine in lymphoma

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Westin%20JR%5BAuthor%5D%20axicabtagene%20ZUMA-7

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [ZUMA-7](https://onco.cc/trials/zuma-7/)
- key papers: [Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma](https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/), [ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early](https://onco.cc/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/jason-westin.json